Physician profile
Christopher Degroat
NPI 1528471091
$42,712.32
in general payments reported to CMS, 2019-2025
19 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $74.53 · 2022: $6,042 · 2023: $17K · 2024: $7,573 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $6,800 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,170 · Food and Beverage: $2,166 · Honoraria: $725 · Travel and Lodging: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,564.00 |
| Consulting Fee | $6,800.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,170.00 |
| Food and Beverage | $2,166.24 |
| Honoraria | $725.00 |
| Travel and Lodging | $670.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $22,045.25 | 2022-2025 | Kengreal, Cleviprex |
| Abbott Laboratories | $15,900.47 | 2019-2025 | Diamondback Coronary, Esprit, Diamondback Peripheral |
| Cardiovascular Systems INC. | $3,509.54 | 2022-2023 | Diamondback Coronary |
| Pfizer INC. | $371.99 | 2019-2025 | |
| Amgen INC. | $246.23 | 2019-2025 | Repatha, Repatha |
| Stryker Corporation | $137.60 | 2025 | Artix Mt |
| Abiomed | $121.39 | 2024 | Impella |
| Astellas Pharma US INC | $91.80 | 2019 | |
| Novo Nordisk INC | $69.80 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $59.15 | 2020-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $35.02 | 2023 | |
| Shockwave Medical, INC | $26.10 | 2025 | |
| Bard Peripheral Vascular, INC. | $24.51 | 2025 | Rotarexs 6 F X 135 Cm |
| Kiniksa Pharmaceuticals International, Plc | $21.04 | 2024 | Arcalyst |
| Akcea Therapeutics, INC. | $15.39 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.04 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $11.64 | 2019 | |
| Lantheus Medical Imaging, INC. | $11.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Degroat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.